Molecular testing for indeterminate thyroid nodules

An "Indeterminate" Thyroid Nodule — What It Really Means

If you have been told your thyroid nodule is indeterminate, it can sound alarming — but it is not a cancer diagnosis. It simply means the FNAC biopsy could not place the nodule clearly into the benign or the cancerous group. The cells showed some features that need a closer look, without being definite either way.

Pathologists report this using the Bethesda system, usually as category III or IV. Most nodules in these categories turn out to be benign. In the past, the only sure way to know was a diagnostic operation — surgery done partly to find the answer. That meant some people had surgery they did not, in hindsight, need.

Molecular testing changed that. By reading the genes inside the nodule cells — including an indeterminate nodule gene test for markers such as BRAF — it adds information to the picture, so the decision about surgery can be made with more confidence and fewer unnecessary steps.

What Molecular Testing Is For — and What It Is Not

The job of molecular testing is to refine the risk for a nodule that the biopsy could not classify. It moves an indeterminate nodule towards "more likely benign" or "more likely cancer", so your team can choose the right next step — close monitoring with ultrasound, or surgery — rather than defaulting to an operation to find out.

It is helpful to be clear about what it is not. It is not a final yes-or-no diagnosis on its own, and it is not the inherited (family) genetic test some people worry about. It reads the changes that happened inside the nodule itself, not the genes you were born with. That is why a BRAF result, for example, is always read alongside your ultrasound and biopsy — never in isolation.

If you already have an FNAC report that says indeterminate, Bethesda III or Bethesda IV, you are welcome to have it reviewed for free — sometimes the right next step is simpler than it first appears.

How Molecular Testing of a Thyroid Nodule Works, Step by Step

The process is built on tests you may have already had. In most cases it adds information without adding a new procedure — here is the usual order.

1. 1

   An FNAC biopsy is taken first

   A thin needle, usually guided by ultrasound, draws a small sample of cells from the nodule. A pathologist examines them and classifies the result using the Bethesda system.

2. 2

   The result comes back indeterminate

   If the cells cannot be clearly called benign or cancer — typically Bethesda III or IV — molecular testing becomes useful. A clearly benign or clearly cancerous result usually does not need it.

3. 3

   The same sample is tested for gene changes

   The cells already collected are analysed for markers such as BRAF and other genes. Often no second needle is needed; occasionally a small repeat FNAC is requested if there are too few cells.

4. 4

   The result refines the risk

   The markers shift the nodule towards "more likely benign" or "more likely cancer". It is a risk estimate, read together with your ultrasound and biopsy — not a stand-alone verdict.

5. 5

   A tumour board decides the next step

   Surgical, medical and pathology specialists review the full picture together and agree whether to watch the nodule with ultrasound or proceed with surgery — matched to your individual case.

What an Indeterminate Nodule Gene Test Actually Reads

A molecular panel checks the nodule cells for a set of genetic changes. You do not need to know each one — your specialist interprets them together — but here is what they mean in plain language.

• BRAF (including BRAF V600E) — the most common change linked with papillary thyroid cancer; when present, it raises the likelihood that a nodule is cancer
• RAS gene changes — found in some follicular-type nodules; they nudge the risk estimate and help guide whether surgery is needed
• Gene fusions (such as RET/PTC) — rearrangements that can point towards certain thyroid cancers and inform the treatment plan
• Gene expression patterns — some panels read the activity of many genes together to flag a nodule as more likely benign or more likely cancer
• The overall risk read-out — the lab combines these markers into one estimate, which the tumour board weighs with your ultrasound and biopsy

Want to know whether any of these apply to your nodule? Speak to a CION thyroid specialist — we explain the report before anything else is ordered.

What Happens After Your Molecular Result

The molecular result is a step in a plan, not the end of it. A low-risk result can support watching the nodule with regular ultrasound — sparing a diagnostic operation that may not have been needed. A higher-risk result, especially with a BRAF change, helps your team plan the right surgery and follow-up without delay.

Either way, the result is taken to a multidisciplinary tumour board, where surgical, medical and pathology specialists agree on the approach together — rather than relying on one doctor's opinion. The size of the nodule, your ultrasound features and your own preferences are all part of that conversation.

To understand the wider pathway, see how the diagnosis fits together on our thyroid cancer diagnosis page, what an indeterminate report means on the Bethesda FNAC results page, and the treatment options on our thyroid cancer treatment in Hyderabad page. For the full picture, visit the main thyroid cancer hub.

Refining the risk before deciding on surgery is what lets your care be matched precisely to your situation — so nothing is over-treated, and nothing is missed.

People Who Got a Clearer Answer — and Avoided Tests They Didn't Need

Real stories from patients who brought an indeterminate report to our team, got a clear next step, and walked the journey with us.

Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your situation. This page is periodically reviewed and updated by CION's medical team in line with current clinical guidelines.

Thyroid Cancer Topics

Browse our complete guide to thyroid cancer — types, symptoms, causes, tests, stages and treatment. Tap any topic to read more.